3.05
Schlusskurs vom Vortag:
$3.01
Offen:
$2.98
24-Stunden-Volumen:
486.21K
Relative Volume:
0.50
Marktkapitalisierung:
$500.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-9.2424
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+5.17%
1M Leistung:
+8.16%
6M Leistung:
-14.57%
1J Leistung:
-36.59%
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SVRA
Savara Inc
|
3.05 | 500.64M | 0 | -54.70M | -51.36M | -0.33 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
2023-11-07 | Eingeleitet | Guggenheim | Buy |
2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
2017-09-22 | Eingeleitet | Jefferies | Buy |
2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. Announces Equity Awards for New Employees - MSN
JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - The Joplin Globe
Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara Inc ends sales agreement with Evercore By Investing.com - Investing.com South Africa
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
Savara Inc. (SVRA) reports earnings - Quartz
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):